Orthofix Medical Business Summary

Orthofix Medical Inc. (OFIX) is a global medical technology company specializing in musculoskeletal healing, generating revenue through the sale of spinal hardware, bone growth therapies, and limb reconstruction solutions. The company operates via two primary business segments: Global Spine, which encompasses spinal implants, regenerative biologics, and bone growth stimulators, and Global Orthopedics (rebranded as Limb Reconstruction in late 2025), focusing on fracture repair and deformity correction. Following its 2023 merger with SeaSpine, Orthofix has increasingly leveraged enabling technologies, specifically the 7D FLASH™ Navigation System, to enhance surgical precision and drive procedural pull-through. The company competes directly with industry leaders such as Medtronic, Globus Medical, and Zimmer Biomet, positioning itself as a high-growth, mid-tier challenger aiming to reach the $1 billion annual revenue mark through its diversified portfolio of surgical and non-surgical therapies. The company was founded in 1980 in Verona, Italy, by Dr. Giovanni De Bastiani, an orthopedic researcher who pioneered the "dynamization" concept of bone healing. Current leadership is headed by President and CEO Massimo Calafiore, who brought extensive industry experience from LimaCorporate and NuVasive upon joining in early 2024. The executive suite includes CFO Julie Andrews, a former finance leader at Wright Medical and Medtronic, and Chief Enabling Technologies Officer Beau Standish, Ph.D., the former co-founder and CEO of 7D Surgical. The Board of Directors is chaired by Michael Finegan, a former Orthofix Chief Strategy Officer and current CEO of Acera Surgical. Notable institutional investors include Engine Capital Management, Rubric Capital Management, and Paradigm Capital Management, which collectively maintain significant stakes as the company pursues its post-merger integration and global expansion strategy.